Educational Resources
Educational Resources
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions. View the full press release.
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program. View the full press release.
Information on Tennessee State Legislation on Step Therapy
The state of Tennessee has enacted restrictions on the use of step therapy for patients with metastatic cancer. This prohibits insurers from requiring a patient with stage four metastatic cancer† to undergo a step therapy protocol. Additional information on the impact of the law, including the types of insurance products that are covered and the effective date, are described in the resource below:
Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma
Posted on 01/15/2026
View the full publication:
View the Plain Language Summary of the publication
© Johnson & Johnson and its affiliates 2025. 12/25 CP-557697v1
Help patients explore everything CAR T Cell Therapy
Posted on 11/12/2025
A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit www.explorecelltherapy.com or download the resource below to learn more.
Patient Out-of-Pocket (OOP) Costs for Covered Medicare Part D Drugs will be Capped in 2026
Posted on 11/12/2025
The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3
In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.
Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.
Help patients explore everything CAR T Cell Therapy
Posted on 11/12/2025
A patient and caregiver website to learn more and find resources about each step of the CAR T cell therapy journey. Visit www.explorecelltherapy.com or download the resource below to learn more.
Patient Out-of-Pocket (OOP) Costs for Covered Medicare Part D Drugs will be Capped in 2026
Posted on 11/12/2025
The Inflation Reduction Act of 2022 included several provisions to reduce OOP costs for Medicare Part D medicines:¹-3
In 2026, $2,100 is the total maximum OOP cost patients will pay for their covered Part D drugs. This includes their annual deductible.
Patients have the option to spread their OOP costs out over the course of the year by opting in to the Medicare Prescription Payment Plan.
CONSIDERATIONS FOR NEOADJUVANT AND ADJUVANT THERAPY
Posted on 11/12/2025
In addition to surgery, with the evolution of new treatment options, surgeons play a role in referral of patients to medical oncologists or the multidisciplinary team. Coordination with the medical oncologist and the entire care team can help facilitate the development of a treatment plan for patients. The resource will review some factors that may be relevant when considering neoadjuvant and adjuvant therapies.
Learn about CAR-T Cell Therapy in Earlier Lines of Treatment for Relapsed or Refractory Multiple Myeloma
Posted on 11/6/2025
To view the full publication, please refer to San-Miguel, J, et al. N Engl J Med. 2023;389(4):335-347 or click the resource below to view the Plain Language Summary of Publication of this article.
Copyright © Tennessee Oncology Practice Society. All rights reserved.
Privacy Policy